Compare Novavax Inc (NVAX) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

Novavax IncTrade

Invesco NASDAQ 100 ETFTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Invesco NASDAQ 100 ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Invesco NASDAQ 100 ETF trades at $294.7. Which is the better fit depends on your goals.

	NVAX	QQQM
Market Cap	$1.68B	—
Sector	Health	Broad Market / Factor
52-Week High	$11.19	$307.23
52-Week Low	$6.22	$229.87
Enterprise Value	$1.26B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

Invesco NASDAQ 100 ETF

QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.

The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVAX

Novavax shifts focus from COVID vaccine sales to licensing its vaccine tech globally.Seeking Alpha · 16 hours agoBullish View details →

QQQM

TQQQ returned 59.18% vs. QQQ's 24.99%, but leverage costs and daily resets reduce its triple return over time.24/7 Wall Street · 15 hours agoNeutral SCHG preferred over QQQM for broader growth exposure and lower cost, while QQQM suits pure Nasdaq-100 focus.Seeking Alpha · 21 hours agoBullish QQQM ETF offers lower fees than QQQ, saving investors thousands over decades with identical Nasdaq-100 exposure.24/7 Wall Street · 1 day agoNeutral View details →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.